Clinical Trials
30 trialsNCT06780670 2026-05-27
PSMAcTION
Novartis
Phase 2/3 Recruiting
NCT07129993 2026-05-14
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07106762 2026-05-12
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT03706365 2026-04-24
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting
NCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT03022825 2025-10-16
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
ImmunityBio, Inc.
Phase 2/3 Active not recruiting
NCT04838626 2025-10-07
GuideView
Novartis
Phase 2/3 Completed
NCT03348670 2025-08-17
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT06879145 2025-06-18
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Recruiting
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting
NCT05381103 2025-01-31
PSMA-PET to Guide Prostatectomy
Five Eleven Pharma, Inc.
Phase 2/3 Recruiting
NCT03410693 2022-09-28
FORT-1
Bayer
Phase 2/3 Completed
NCT02981368 2021-08-09
OSPREY
Progenics Pharmaceuticals, Inc.
Phase 2/3 Completed
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT01475266 2017-03-29
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Nippon Kayaku Co., Ltd.
Phase 2/3 Terminated
NCT02829775 2017-01-09
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
Hoffmann-La Roche
Phase 2/3 Completed
NCT00406068 2016-07-28
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
Bioniche Life Sciences Inc.
Phase 2/3 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00420888 2015-07-22
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Active Biotech AB
Phase 2/3 Completed
NCT01316874 2015-06-12
Bladder Cancer
Endo Pharmaceuticals
Phase 2/3 Completed
NCT00215683 2015-04-01
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT00295802 2014-02-07
Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer
EDAP TMS S.A.
Phase 2/3 Unknown
NCT00332280 2013-03-20
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Auron Healthcare GmbH
Phase 2/3 Terminated
NCT00004071 2012-09-11
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
Pfizer
Phase 2/3 Completed
NCT00268892 2010-12-24
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT00312442 2010-06-02
Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy
STEBA France
Phase 2/3 Terminated
NCT00043576 2009-03-12
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
Novacea
Phase 2/3 Unknown
NCT00127478 2007-11-29
A Long Term Safety Study With Atrasentan
Abbott
Phase 2/3 Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed